General Information of Drug (ID: DMGTAWC)

Drug Name
RKI-1447 Drug Info
Synonyms RKI1447; compound 5g [PMID 23275831]
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
60138149
TTD Drug ID
DMGTAWC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
KD025 DM548TK Psoriasis vulgaris EA90 Phase 2 [2]
INS-117548 DMA46DO Glaucoma/ocular hypertension 9C61 Phase 1 [3]
GSK269962A DM5I2HL Inflammation 1A00-CA43.1 Clinical trial [4]
PMID28048944-Compound-19 DMPT3V9 N. A. N. A. Patented [5]
PMID28048944-Compound-3 DM1BN74 N. A. N. A. Patented [5]
PMID28048944-Compound-7 DMXZ368 N. A. N. A. Patented [5]
PMID28048944-Compound-4 DMJAUWG N. A. N. A. Patented [5]
PMID28048944-Compound-5 DMAB987 N. A. N. A. Patented [5]
PMID28048944-Compound-6 DM5RCBV N. A. N. A. Patented [5]
PMID28048944-Compound-2 DM9ZXOP N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting PAK-1 protein kinase (PAK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID20005102C1 DMMESBW Discovery agent N.A. Investigative [6]
Il-94 DMPNQ27 Discovery agent N.A. Investigative [7]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Netarsudil DM0LPI9 Open-angle glaucoma 9C61 Approved [8]
SAR-407899 DMF95KD Diabetic nephropathy GB61.Z Phase 2 [9]
H-1152 DM8XH3S Pulmonary arterial hypertension BB01.0 Phase 2 [10]
INS-117548 DMA46DO Glaucoma/ocular hypertension 9C61 Phase 1 [3]
GSK269962A DM5I2HL Inflammation 1A00-CA43.1 Clinical trial [4]
PMID28048944-Compound-19 DMPT3V9 N. A. N. A. Patented [5]
PMID28048944-Compound-3 DM1BN74 N. A. N. A. Patented [5]
PMID28048944-Compound-7 DMXZ368 N. A. N. A. Patented [5]
PMID28048944-Compound-4 DMJAUWG N. A. N. A. Patented [5]
PMID28048944-Compound-5 DMAB987 N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Protein kinase N1 (PKN1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID22136433C20 DMI8217 Discovery agent N.A. Investigative [11]
Drug Name Drug ID Indication ICD 11 Highest Status REF
ISIS-DMPK DMH32LC Myotonic dystrophy 8C71.0 Phase 1/2 [12]
PRO-135 DMA2SBL Myotonic dystrophy 8C71.0 Investigative [13]
2-MOE phosphorothioate gapmers DM4IJXW Myotonic dystrophy 8C71.0 Investigative [13]
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID22902653C30 DMXDTPL Discovery agent N.A. Investigative [14]
PMID22902653C31 DMWVTAE Discovery agent N.A. Investigative [14]
PMID22902653C35 DMLVKPG Discovery agent N.A. Investigative [14]
PMID19831390C14 DMIECOF Discovery agent N.A. Investigative [15]
Drug(s) Targeting Myosin light kinase (MYLK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ME-3407 DMO84TL Duodenal ulcer DA63 Phase 2 [16]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CDC42 binding protein kinase alpha (DMPK-like alpha) TT5Z0EF MRCKA_HUMAN Inhibitor [1]
DMPK messenger RNA (DMPK mRNA) TTZQTY2 DMPK_HUMAN Inhibitor [1]
LIM domain kinase-1 (LIMK-1) TTWL9TY LIMK1_HUMAN Inhibitor [1]
Myosin light kinase (MYLK) TT18ETS MYLK_HUMAN Inhibitor [1]
PAK-1 protein kinase (PAK1) TTFN95D PAK1_HUMAN Inhibitor [1]
Protein kinase N1 (PKN1) TTSL41O PKN1_HUMAN Inhibitor [1]
Rho-associated protein kinase 1 (ROCK1) TTZN7RP ROCK1_HUMAN Inhibitor [1]
Rho-associated protein kinase 2 (ROCK2) TTGWKQJ ROCK2_HUMAN Inhibitor [1]

References

1 Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709.
2 Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9.
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
5 Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
6 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
7 PAK1: A Therapeutic Target for Cancer Treatment. ACS Med Chem Lett. 2013 Mar 19;4(5):431-2.
8 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
9 The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012 May;30(5):980-9.
10 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
11 7,8-dichloro-1-oxo-beta-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J Med Chem. 2012 Jan 12;55(1):403-13.
12 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1505).
14 Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8.
15 Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma. J Med Chem. 2009 Nov 12;52(21):6515-8.
16 ME-3407, a new antiulcer agent, inhibits acid secretion by interfering with redistribution of H(+)-K(+)-ATPase. Am J Physiol. 1997 May;272(5 Pt 1):G1122-34.